Close Menu

NEW YORK (GenomeWeb) – The litigants in an intellectual property lawsuit over liquid biopsy technology have each levied misconduct allegations against the other.

Personal Genome Diagnostics (PGDx) has alleged that Guardant Health improperly obtained at least three patents for liquid biopsy technology. And Guardant has suggested that PGDx's "infringement of the patents-in-suit is deliberate and willful and constitutes egregious misconduct."

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.